Primidone is an antiepileptic drug from the group of barbiturates . In the human body, it is partially metabolized to phenobarbital , possessing some of its pharmacological properties. Side effects are observed more often than phenobarbital.
| Primidon | |
|---|---|
 | |
| Chemical compound | |
| IUPAC | 5-ethyl-5-phenyl-hexahydropyrimidine-4,6-dione |
| Gross formula | C 12 H 14 N 2 O 2 |
| Molar mass | 218.252 g / mol |
| Cas | |
| PubChem | |
| Drugbank | |
| Classification | |
| ATX | |
| Pharmacokinetics | |
| Bioavailable | ~ 100% [1] |
| Plasma Protein Binding | 25% [1] |
| Metabolism | Liver |
| The half-life. | Primidone: 5-18 hours, Phenobarbital: 75-120 hours, [1] PEMA: 16 hours [2] Time to reach steady state: Primidone: 2-3 days, Phenobarbital & PEMA 1-4weeks [3] |
| Excretion | Kidney |
| Route of administration | |
| orally | |
| Other names | |
| Hexamidine | |
Properties
By chemical structure, it is deoxybarbiturate ; differs from phenobarbital in that in position 2 the carbonyl group (C == O) is replaced by methylene (CH2). This chemical modification of the molecule led to the preparation with a strong anticonvulsant effect and less hypnotic effect.
By physical properties: white crystalline powder, practically insoluble in water, slightly soluble in alcohol.
Notes
- ↑ 1 2 3 Ochoa, Juan G; Riche, Willise. Antiepileptic Drugs: An Overview . eMedicine . eMedicine, Inc. (2005). Date of treatment July 2, 2005. Archived February 3, 2012.
- ↑ CDER, US DEPARTMENT OF HEALTH AND HUMAN SERVICES. Primidone (Mysoline) . Pharmacology Guide for Brain Injury Treatment . Brain Injury Resource Foundation (2003–2005). Date of treatment July 2, 2005. Archived February 3, 2012.
- ↑ Yale Medical School, Department of Laboratory Medicine. Therapeutic Drug Levels . YNHH Laboratory Manual - Reference Documents . Yale Medical School (1998). Date of treatment July 13, 2005. Archived February 3, 2012.